A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ina Rhee, M.D., Ph.D.
Genentech, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
40 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
South Brisbane, Queensland, Australia
- Facility name not stated
Woodville South, South Australia, Australia
- Facility name not stated
Footscray, Victoria, Australia
- Facility name not stated
Heidelberg, Victoria, Australia
- Facility name not stated
Melbourne, Victoria, Australia
- Facility name not stated
Brussels, Belgium
- Facility name not stated
Brussels, Belgium
- Facility name not stated
Leuven, Belgium
- Facility name not stated
Gdansk, Poland
- Facility name not stated
Krakow, Poland
- Facility name not stated
Poznan, Poland
- Facility name not stated
Warsaw, Poland
- Facility name not stated
Barcelona, Barcelona, Spain
- Facility name not stated
Barcelona, Barcelona, Spain
- Facility name not stated
Santander, Cantabria, Spain
- Facility name not stated
Seville, Sevilla, Spain
- Facility name not stated
Valencia, Valencia, Spain
- Facility name not stated
Birmingham, Alabama, United States
- Facility name not stated
Scottsdale, Arizona, United States
- Facility name not stated
Bakersfield, California, United States
- Facility name not stated
Fullerton, California, United States
- Facility name not stated
Los Angeles, California, United States
- Facility name not stated
Los Angeles, California, United States
- Facility name not stated
Pasadena, California, United States
- Facility name not stated
San Luis Obispo, California, United States
- Facility name not stated
Aurora, Colorado, United States
- Facility name not stated
Washington D.C., District of Columbia, United States
- Facility name not stated
Jacksonville, Florida, United States
- Facility name not stated
Ocala, Florida, United States
- Facility name not stated
Port Saint Lucie, Florida, United States
- Facility name not stated
Lawrenceville, Georgia, United States
- Facility name not stated
Marietta, Georgia, United States
- Facility name not stated
Harvey, Illinois, United States
- Facility name not stated
Indianapolis, Indiana, United States
- Facility name not stated
Boston, Massachusetts, United States
- Facility name not stated
Boston, Massachusetts, United States
- Facility name not stated
Rochester, Minnesota, United States
- Facility name not stated
Las Vegas, Nevada, United States
- Facility name not stated
Durham, North Carolina, United States
- Facility name not stated
Philadelphia, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2011
- Primary completion
- 28 Feb 2014
- Completion
- 28 Feb 2014
- Last update posted
- 26 Aug 2016
- Registered enrollment
- 127
- Registry id
- NCT01399684
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.